References
- Kiesewetter B, Raderer M. Underlying autoimmune diseases are not aggravated during treatment with lenalidomide in patients with mucosa-associated lymphoid tissue (MALT) lymphoma. Leuk Lymphoma 2014. [Epub ahead of print]
- Montefusco V, Galli M, Spina F, et al. Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide. Leuk Lymphoma 2014; [Epub ahead of print].
- Dasanu CA, Alexandrescu DT. A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma. Eur J Haematol 2009;82:231–234.
- Darabi K, Kantamnei S, Wiernik PH. Lenalidomide-induced warm autoimmune hemolytic anemia. J Clin Oncol 2006;24:e59.
- Brauer DL, Edelman B, Rapoport AP, et al. Plasma exchange and rituximab treatment for lenalidomide-associated cold agglutinin disease. Transfusion 2012;52:2432–2435.
- Sun WL, Köck L, Walder A, et al. Successful treatment of MDS with lenalidomide, complicated by transient autoimmune hemolysis. Ann Hematol 2010;89:327–329.
- Figaro MK, Clayton W Jr, Usoh C, et al. Thyroid abnormalities in patients treated with lenalidomide for hematological malignancies: results of a retrospective case review. Am J Hematol 2011;86: 467–470.
- Carver JR, Nasta S, Chong EA, et al. Myocarditis during lenalidomide therapy. Ann Pharmacother 2010;44:1840–1843.
- Davies F, Baz R. Lenalidomide mode of action: linking bench and clinical findings. Blood Rev 2010;24(Suppl. 1):S13–S19.